Options for Second-Line Treatment in Metastatic Colorectal Cancer

James J. Lee, MD, PhD, and Weijing Sun, MD

  Abstract: Colorectal cancer (CRC) remains a major public health problem in the United States and worldwide. The majority of patients who have CRC eventually present […]

B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1   Stefan Koehrer, MD, and Jan A. Burger, MD The authors are affiliated with […]

Should EGFR Tyrosine Kinase Inhibitors Be Used in Non–Small Cell Lung Cancer in the Absence of EGFR Mutations?

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1   Tyrosine kinase inhibitors (TKIs) that block epidermal growth factor receptor (EGFR) clearly work […]

When to Initiate Treatment With Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1   Neal D. Shore, MD, FACS Medical Director, CPI Carolina Urologic Research Center Atlantic […]

Emerging Phase 3 Data in Relapsed/Refractory Metastatic Colorectal Cancer

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1   Richard Goldberg, MD Interim Division Director of Medical Oncology Physician-in-Chief, OSUCCC-James Cancer Hospital […]

The Impact of Value-Based Insurance Design on Oncology Drugs

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1   A. Mark Fendrick, MD Professor, Internal Medicine Director, Center for Value-Based Insurance Design […]

Can Global Assays Make Anticoagulation Safer and More Effective?

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1   H. Coenraad Hemker, MD, PhD Emeritus Professor Cardiovascular Research Institute Maastricht Maastricht, the […]

Are Chimeric Antigen Receptor T Cells Ready for Prime Time?

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1   Renier J. Brentjens, MD, PhD Director, Cellular Therapeutics Memorial Sloan Kettering Cancer Center […]

January News

Ixazomib Approved for Use in Myeloma   The US Food and Drug Administration (FDA) approved ixazomib (Ninlaro, Takeda/Millennium) on November 20 for use in patients with multiple […]

Letter From the Editor: The Children Act

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1 The white was Matua Sauvignon Blanc, from Marlborough (New Zealand, not the prestigious girls’ […]

Back to Archive